- Home
- IMNM vs SSMR Comparison
IMNM vs SSMR Comparison
Compare IMNM & SSMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | SSMR |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | IMNM | SSMR |
|---|---|---|
| Price | $19.53 | $14.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $35.20 | $19.17 |
| AVG Volume (30 Days) | ★ 1.3M | 391.5K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,747.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.53 | $12.51 |
| 52 Week High | $30.06 | $19.61 |
Technical Indicators
Market Signals| Indicator | IMNM | SSMR |
|---|---|---|
| Relative Strength Index (RSI) | 30.12 | 43.70 |
| Support Level | $19.39 | $14.51 |
| Resistance Level | $23.48 | $15.33 |
| Average True Range (ATR) | 1.12 | 0.71 |
| MACD | -0.27 | -0.06 |
| Stochastic Oscillator | 13.81 | 30.39 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.